Agile Therapeutics (AGRX) Scheduled to Post Quarterly Earnings on Thursday

Agile Therapeutics (NASDAQ:AGRXGet Rating) is set to issue its quarterly earnings data after the market closes on Thursday, August 11th. Parties that are interested in registering for the company’s conference call can do so using this link.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last posted its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share for the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. The company had revenue of $1.76 million for the quarter. On average, analysts expect Agile Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Agile Therapeutics Trading Up 6.4 %

Shares of AGRX stock opened at $0.57 on Thursday. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $6.81. Agile Therapeutics has a 52 week low of $0.49 and a 52 week high of $50.40. The company has a market cap of $2.57 million, a PE ratio of -0.02 and a beta of 1.22.

Institutional Investors Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC increased its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXGet Rating) by 281.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 621,200 shares of the specialty pharmaceutical company’s stock after buying an additional 458,300 shares during the period. Renaissance Technologies LLC owned about 16.94% of Agile Therapeutics worth $130,000 at the end of the most recent reporting period. Institutional investors own 27.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Maxim Group raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 26th. StockNews.com assumed coverage on shares of Agile Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.

Agile Therapeutics Company Profile

(Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also

Earnings History for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.